ebronucimab   Click here for help

GtoPdb Ligand ID: 13786

Synonyms: AK-102 | AK102 | inusimab
Approved drug
ebronucimab is an approved drug
Compound class: Antibody
Comment: Ebronucimab (AK-102) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol from the circulation. Ebronucimab was developed for patients at high risk for cardiovascular disease when lipid-lowering cannot be achieved with statins or statins + ezetimibe.
No information available.
Summary of Clinical Use Click here for help
The Chinese drug regulator (NMPA) approved ebronucimab (YiXining®) in September 2024 [1], to treat primary hypercholesterolaemia and mixed hyperlipidaemia in combination with statins ± other lipid-lowering therapies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05255094 A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia Phase 3 Interventional Akeso 2
NCT05255458 A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia Phase 3 Interventional Akeso
NCT04358432 A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia Phase 2 Interventional Akeso
NCT04173793 A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2 Interventional Akeso